High-dose cyclophosphamide as salvage therapy for severe aplastic anemia

Experimental Hematology

Volumn 32, Issue 5, 2004, Pages 435-440

  Brodsky, Robert A ^a,c   Chen, Allen R ^a   Brodsky, Isadore ^b   Jones, Richard J ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c Division of Hematologic Malignancies   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE;

ADOLESCENT; ADULT; APLASTIC ANEMIA; ARTICLE; CELL COUNT; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SCREENING; ERYTHROCYTE TRANSFUSION; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MYELODYSPLASTIC SYNDROME; NEUTROPHIL; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PATIENT; PRIORITY JOURNAL; REMISSION; SALVAGE THERAPY; THROMBOCYTE TRANSFUSION; TIME;

ADOLESCENT; ADULT; ANEMIA, APLASTIC; CHILD; CYCLOPHOSPHAMIDE; FEMALE; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; INFECTION; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; REMISSION INDUCTION; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 2442490982     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2004.02.002     Document Type: Article

References (39)

1. Young N.S. Acquired aplastic anemia. JAMA. 282:1999;271-278
2. Storb R., Leisenring W., Anasetti C., et al. Long-term follow-up of allogeneic marrow transplants in patients with aplastic anemia conditioned by cyclophosphamide combined with antithymocyte globulin. Blood. 89:1997;3890-3891
3. Storb R., Blume K.G., O'Donnell M.R., et al. Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: the experience in four centers. Biol Blood Marrow Transplant. 7:2001;39-44
4. Passweg J.R., Socie G., Hinterberger W., et al. Bone marrow transplantation for severe aplastic anemia: has outcome improved? Blood. 90:1997;858-864
5. Bacigalupo A., Oneto R., Bruno B., et al. Current results of bone marrow transplantation in patients with acquired severe aplastic anemia. Report of the European Group for Blood and Marrow transplantation. On behalf of the Working Party on Severe Aplastic Anemia of the European Group for Blood and Marrow Transplantation. Acta Haematol. 103:2000;19-25
6. Frickhofen N., Kaltwasser J.P., Schrezenmeier H., et al. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. N Engl J Med. 324:1991;1297-1304
7. Bacigalupo A., Bruno B., Saracco P., et al. Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. Blood. 95:2000;1931-1934
8. Rosenfeld S., Follmann D., Nunez O., Young N.S. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA. 289:2003;1130-1135
9. Deeg H.J., Seidel K., Casper J., et al. Marrow transplantation from unrelated donors for patients with severe aplastic anemia who have failed immunosuppressive therapy. Biol Blood Marrow Transplant. 5:1999;243-252
10. Davies S.M., Wagner J.E., Defor T., et al. Unrelated donor bone marrow transplantation for children and adolescents with aplastic anaemia or myelodysplasia. Br J Haematol. 96:1997;749-756
11. Margolis D., Camitta B., Pietryga D., et al. Unrelated donor bone marrow transplantation to treat severe aplastic anaemia in children and young adults. Br J Haematol. 94:1996;65-72
12. Dini G., Cancedda R., Locatelli F., et al. Unrelated donor marrow transplantation: an update of the experience of the Italian Bone Marrow Transplant Group (GITMO). Haematologica. 85:2000;30-36
13. Baran D.T., Griner P.F., Klemperer M.R. Recovery from aplastic anemia after treatment with cyclophosphamide. N Engl J Med. 295:1976;1522-1523
14. Brodsky R.A., Sensenbrenner L.L., Jones R.J. Complete remission in acquired severe aplastic anemia following high-dose cyclophosphamide. Blood. 87:1996;491-494
15. Brodsky R.A., Sensenbrenner L.L., Smith B.D., et al. Durable treatment-free remission following high-dose cyclophosphamide for previously untreated severe aplastic anemia. Ann Intern Med. 135:2001;477-483
16. Jaime-Perez J.C., Gonzalez-Llano O., Gomez-Almaguer D. High-dose cyclophosphamide in the treatment of severe aplastic anemia in children. Am J Hematol. 66:2001;71
17. Li Z., Yin S., Xie S., Ma L., Nie D., Xsu L. Treatment of severe aplastic anemia using high-dose cyclophosphamide alone in China. Haematologica. 85:2000;E06
18. Tisdale J.F., Dunn D.E., Geller N., et al. High-dose cyclophosphamide in severe aplastic anaemia: a randomised trial. Lancet. 356:2000;1554-1559
19. Brodsky R.A., Petri M., Smith B.D., et al. Immunoablative high-dose cyclophosphamide without stem cell rescue for refractory severe autoimmune disease. Ann Intern Med. 129:1998;1031-1035
20. Moyo V.M., Smith D., Brodsky I., Crilley P., Jones R.J., Brodsky R.A. High-dose cyclophosphamide for refractory autoimmune hemolytic anemia. Blood. 100:2002;704-706
21. Petri M., Jones R.J., Brodsky R.A. High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis Rheum. 48:2003;166-173
22. Drachman D.B., Jones R.J., Brodsky R.A. Treatment of refractory myasthenia: "rebooting" with high-dose cyclophosphamide. Ann Neurol. 53:2003;29-34
23. Camitta B.M., Thomas E.D., Nathan D.G., et al. A prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia. Blood. 53:1979;504-514
24. Bennett J.M., Catovsky D., Daniel M.T., et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 51:1982;189-199
25. Mukhina G.L., Buckley J.T., Barber J.P., Jones R.J., Brodsky R.A. Multilineage glycosylphosphatidylinositol anchor deficient hematopoiesis in untreated aplastic anemia. Br J Haematol. 115:2001;476-482
26. Brodsky R.A., Mukhina G.L., Nelson K.L., Lawrence T.S., Jones R.J., Buckley J.T. Resistance of paroxysmal nocturnal hemoglobinuria cells to the glycosylphosphatidylinositol-binding toxin aerolysin. Blood. 93:1999;1749-1756
27. Hall S.E., Rosse W.F. The use of monoclonal antibodies and flow cytometry in the diagnosis of paroxysmal nocturnal hemoglobinuria. Blood. 87:1996;5332-5340
28. Brodsky R.A., Mukhina G.L., Li S., et al. Improved detection and characterization of paroxysmal nocturnal hemoglobinuria using fluorescent aerolysin. Am J Clin Pathol. 114:2000;459-466
29. Tisdale J.F., Maciejewski J.P., Nunez O., Rosenfeld S.J., Young N.S. Late complications following treatment for severe aplastic anemia (SAA) with high-dose cyclophosphamide (Cy): follow-up of a randomized trial. Blood. 100:2002;4668-4670
30. Deeg H.J., Shulman H.M., Schmidt E., Yee G.C., Thomas E.D., Storb R. Marrow graft rejection and veno-occlusive disease of the liver in patients with aplastic anemia conditioned with cyclophosphamide and cyclosporine. Transplantation. 42:1986;497-501
31. Mayumi H., Umesue M., Nomoto K. Cyclophosphamide-induced immunological tolerance: an overview. Immunobiology. 195:1996;129-139
32. Nomoto K., Eto M., Yanaga K., Nishimura Y., Maeda T. Interference with cyclophosphamide-induced skin allograft tolerance by cyclosporin A. J Immunol. 149:1992;2668-2674
33. Tichelli A., Passweg J., Nissen C., et al. Repeated treatment with horse antilymphocyte globulin for severe aplastic anaemia. Br J Haematol. 100:1998;393-400
34. Di Bona E., Rodeghiero F., Bruno B., et al. Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy. Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Br J Haematol. 107:1999;330-334
35. Socie G., Henry-Amar M., Bacigalupo A., et al. Malignant tumors occurring after treatment of aplastic anemia. N Engl J Med. 329:1993;1152-1157
36. Tichelli A., Gratwohl A., Wursch A., Nissen C., Speck B. Late haematological complications in severe aplastic anaemia. Br J Haematol. 69:1988;413-418
37. Luzzatto L., Bessler M., Rotoli B. Somatic mutations in paroxysmal nocturnal hemoglobinuria: a blessing in disguise? Cell. 88:1997;1-4
38. Hillmen Pand Richards S.J. Implications of recent insights into the pathophysiology of paroxysmal nocturnal haemoglobinuria. Br J Haematol. 108:2000;470-479
39. Chen R., Nagarajan S., Prince G.M., et al. Impaired growth and elevated fas receptor expression in PIGA(+) stem cells in primary paroxysmal nocturnal hemoglobinuria. J Clin Invest. 106:2000;689-696